Initial in vivo investigations on GS-9667 (originally known as CVT-3619), a partial agonist for A1R (IC50 ≈ 6 nM on AC inhibition in adipocytes, via A1R [197]; Ki ≈ 55 nM on A1R, with selectivity over the A2AR > 200-fold, A2BR > 1000-fold and A3R > 20-fold [198]), highlighted its clinical potential as a therapeutic agent for IHD by effectively reducing plasma free fatty acid levels [196,199], without significant side effects in rodents. This evidence concerns the gene ADORA2A and myocardial ischemia.